C6 Antibody

What is the C6 peptide and what is its significance in Lyme borreliosis diagnosis?

The C6 peptide reproduces the sequence of invariable region 6 (IR6) of VlsE, the antigenic variation protein of Borrelia burgdorferi sensu stricto, the causative agent of Lyme disease. This peptide is highly immunogenic and remains antigenically conserved among pathogenic B. burgdorferi strains and genospecies, making it an excellent target for serological diagnosis . Unlike other variable surface molecules, IR6 remains unchanged during antigenic variation and consistently elicits strong antibody responses in infected individuals . The C6 peptide-based enzyme-linked immunosorbent assay (ELISA) has emerged as a sensitive and specific test for the serologic diagnosis of Lyme disease with excellent precision (99-100%) .

How do C6 antibody profiles differ between IgM and IgG responses during infection?

In patients with erythema migrans (EM), the characteristic skin manifestation of early Lyme borreliosis, both IgM and IgG antibodies to B. burgdorferi C6 can be detected. Research shows that approximately 32.8% of patients develop IgM antibodies to Bb C6, while 72.5% develop IgG antibodies . The seroconversion rate is approximately 51.2% for IgM antibodies and significantly higher (88.4%) for IgG antibodies . Interestingly, some patients (15 of 37 in one study) may generate IgG antibodies that react with C6 but not with the full-length VlsE protein, while IgM responses are more frequent for VlsE than for invariable segments . This differential antibody response pattern is important for researchers to consider when developing diagnostic approaches.

What is the relationship between VlsE structure and C6 antibody binding?

The IR6 epitopes appear to be largely concealed from the VlsE molecular surface, as demonstrated by competition experiments. When C6 peptide is used as a competitor for VlsE binding, only about half of serum specimens show >50% inhibition, with a median percent inhibition of 45.5% . This suggests that full-length VlsE-based diagnosis likely detects antibodies to conformational and/or variable region epitopes in addition to IR6 epitopes . Researchers should consider these structural characteristics when designing experiments involving C6 antibody detection or when interpreting results of different assay formats.

How is quantitative measurement of C6 antibody performed?

Quantitative measurement of C6 antibody can be performed using a microtiter plate format ELISA. The methodology involves:

• Coating microtiter plates with C6 multiple-antigenic-peptide

• Diluting test samples (typically 1:1,000) in phosphate saline with Tween 20

• Adding 100 μl of diluted sample to individual microtiter wells and incubating for 30 minutes

• Washing with phosphate saline containing Tween 20

• Incubating with anti-immunoglobulin horseradish peroxidase conjugate

• Washing and adding substrate solution containing 3,3′,5,5′-tetramethylbenzidine

• Measuring optical density values at 650 nm

Antibody levels are calculated using a standard curve produced from optical density values of calibrated controls, with results reported in units/ml (U/ml). The dynamic range of such assays is typically 10 U/ml to >400 U/ml, with interwell variability levels generally less than 10% . This quantitative approach enables precise monitoring of antibody levels over time, which is particularly valuable for treatment response studies.

What is the PHOSPHAN method and how does it enhance C6 antibody detection?

The C6 peptide-based multiplex Phosphorescence Analysis (PHOSPHAN) is a promising method for simultaneously detecting antibodies to several Borrelia antigens. This technique measures antibodies that bind to C6 peptides from different Borrelia genospecies (B. burgdorferi, B. garinii, and B. afzelii) as well as recombinant proteins OspC and VlsE . The multiplex nature of this assay allows researchers to examine the spectrum of antibody responses in a single test, providing a more comprehensive immunological profile than single-antigen tests.

In a study of Russian patients with erythema migrans, PHOSPHAN effectively detected both IgM and IgG antibodies to B. burgdorferi C6, with additional detection of IgG to C6 from B. garinii or B. afzelii . The method provided effective serologic confirmation of Lyme borreliosis and, with high probability, indicated active infection processes.

How do C6 antibody levels change following antibiotic treatment?

Quantitative measurement of C6 antibody levels has revealed significant declines following antibiotic treatment in infected individuals. In a study of B. burgdorferi antibody-positive dogs, those with initial C6 levels ≥29 U/ml showed statistically significant declines at 6 months post-treatment, while those with values <29 U/ml had small, inconsistent changes . The median percent decline in C6 level relative to pretreatment values was 68.0% at 6 months (16 samples; lower 95% confidence limit, 58.3%) and 83.3% at 12 months (29 samples; 95% lower confidence limit, 76.0%) .

This quantifiable decline in C6 antibody levels provides researchers with a useful marker for monitoring treatment efficacy. The data suggest that patients should be stratified based on initial antibody levels when designing studies to assess treatment response, as those with higher initial titers show more consistent and measurable declines.

Can C6 antibody testing be used in vaccinated individuals?

A critical advantage of C6 peptide-based testing is that it does not cross-react with antibodies elicited by vaccination with recombinant OspA (rOspA) vaccine. A study of 29 uninfected individuals vaccinated with the rOspA vaccine demonstrated that none had an antibody response to the C6 peptide . This finding has significant implications for research in regions where Lyme disease vaccination has been implemented, as C6 antibody testing can reliably distinguish between vaccine-induced immunity and natural infection . Researchers can therefore use C6 antibody testing to diagnose Lyme disease in vaccinated individuals without concern for false-positive results due to vaccine-induced antibodies.

What is the diagnostic precision of C6 antibody testing compared to conventional approaches?

The C6 peptide ELISA has shown excellent sensitivity with acute-phase (74%), convalescent-phase (85-90%), and late-phase (100%) specimens in U.S. patients with Lyme disease . Additionally, it demonstrates excellent specificity (99%) and precision (100%) . This performance compares favorably with conventional two-tiered testing (CTTT), which is time-consuming and has low sensitivity in early disease stages .

Modified two-tiered testing (MTTT) incorporating recombinant VlsE and C6 peptide has been developed to address these limitations . Researchers should note that the C6 peptide ELISA can also detect antibodies in patients with culture-confirmed infections caused by either Borrelia garinii or Borrelia afzelii, the predominant genospecies in Europe, due to the antigenic conservation of the IR6 region among B. burgdorferi sensu lato strains .

What are the dominant epitopes within the C6 peptide?

Analysis of the antigenic structure of VlsE has revealed that antigenicity is largely concentrated in IR6, to the exclusion of other invariable regions (IRs) and domains of the molecule . Among the invariable segments studied (IR2, IR4, IR6, and N- and C-terminal domains), IR6 epitopes (represented by the C6 peptide) dominate the immune response. Approximately 78% of patient serum specimens contain antibodies specific to IR6, while <40% respond to the N- or C-terminal domains and <12% respond to either IR2 or IR4 .

How can researchers distinguish between C6 antibody responses to different Borrelia species?

What are the potential improvements to C6-based diagnostic methods?

Current research suggests several directions for enhancing C6-based diagnostics:

• Integration of C6 testing into multiplex assays that simultaneously detect antibodies to multiple Borrelia antigens

• Development of point-of-care tests based on C6 technology for rapid field diagnostics

• Refinement of quantitative C6 assays for more precise monitoring of treatment response

• Investigation of C6 peptide modifications to improve sensitivity while maintaining specificity

• Exploration of the relationship between quantitative C6 antibody levels and clinical outcomes

Researchers should consider these areas when designing future studies to advance Lyme disease diagnostics.

How might C6 antibody testing be integrated into modified two-tiered testing algorithms?

Modified two-tiered testing (MTTT) incorporates recombinant VlsE and C6 peptide to address limitations of conventional approaches . Future research could focus on optimizing these algorithms by:

• Determining the optimal sequence of tests in the MTTT approach

• Evaluating the performance of different C6-based assay formats within MTTT

• Assessing the value of quantitative C6 measurements in MTTT protocols

• Investigating the integration of additional Borrelia antigens alongside C6

• Comparing the performance of different MTTT approaches across various patient populations and geographic regions

Such research could significantly enhance the diagnostic precision for Lyme borreliosis across diverse clinical and epidemiological settings.